The Asia Pacific Penicillin Drug Market would witness market growth of 4.2% CAGR during the forecast period (2023-2030).
A widely used drug for managing and treating different infections is penicillin. It is an ingredient of the class of medications known as beta-lactam antibiotics, including amoxicillin, ampicillin, and other antibiotics. When susceptible organisms cause bacterial infections, penicillin is often used as a therapy. Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, and other gram-negative bacteria like Neisseria meningitidis are merely some of the microorganisms it is effective against.
Penicillin is offered in various dosage forms, including tablets, capsules, solutions, and injections, to accommodate various administration methods and patient requirements. Different dose forms may be used depending on the type of penicillin and the nation's healthcare system. Penicillin prevents the enzymes necessary for the cross-linking of peptidoglycan, a crucial component of the bacterial cell wall, thereby preventing the formation of bacterial cell walls. By weakening the cell wall, this inhibition causes the bacteria to lyse, which ultimately kills bacteria.
The National Library of Medicine reports that from 12.94 DID in 2018 to 14.45 DID in 2019, China's total antibiotic use across all healthcare settings has increased significantly. The consumption of antibiotics in PHCs exceeded 50%, notably in the central regions (59%–68%). According to the Annual Pharmaceutical Production Statistics Report from the Ministry of Health, Labour, and Welfare ("MHLW") of Japan, the Japanese industry for both over the counter and prescription reached a value of US$109 billion in 2020. The market is predicted to expand in this region due to rising antibiotic usage and advancements in the pharmaceutical sector.
The China market dominated the Asia Pacific Penicillin Drug Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1.1 billion by 2030. The Japan market is anticipated to grow at a CAGR of 3.5% during (2023 - 2030). Additionally, The India market would register a CAGR of 4.8% during (2023 - 2030).
Based on Source, the market is segmented into Semisynthetic Penicillin and Natural Penicillin. Based on Spectrum of Activity, the market is segmented into Broad spectrum, Extended spectrum and Narrow spectrum. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Penicillin Drug Market is Projected to reach USD 10.9 Billion by 2030, at a CAGR of 3.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Novartis AG, Lupin Limited, Abbott Laboratories, Cipla Limited, Takeda Pharmaceutical Company Limited, Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd.
By Source
By Spectrum of Activity
By Distribution Channel
By Route of Administration
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
